SCHEMBL22116556

SCHEMBL22116556

CCOc1ccc(C#Cc2ccc(C(=O)OC)nc2)c([N+](=O)[O-])c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 9/20 0.44
▸ SMN1; SMN2 Q16637 5/20 0.44
▸ RAB9A P51151 8/20 0.44
▸ NPC1 O15118 7/20 0.44
▸ MAPK1 P28482 2/20 0.44
▸ POLB P06746 1/20 0.44
▸ KMT2A Q03164 5/20 0.42
▸ MEN1 O00255 4/20 0.42
▸ CYP2C19 P33261 2/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ PKM P14618 2/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ ACACB O00763 1/20 0.41
▸ ALDH1A1 P00352 3/20 0.41
▸ LMNA P02545 1/20 0.41
▸ NFKB1 P19838 1/20 0.40
▸ NFKB2 Q00653 1/20 0.40
▸ RELA Q04206 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22116706 0.92 MAPT (0.44) MAPTSMN1; SMN2RAB9ANPC1MAPK1
SCHEMBL22116532 0.83 ACACB (0.44) MAPTRAB9ANPC1MAPK1ACACB
SCHEMBL22116777 0.81 ACACB (0.44) MAPTRAB9ANPC1MAPK1ACACB
SCHEMBL22134655 0.79 ACACB (0.43) RAB9ANPC1MAPK1ACACB
SCHEMBL31620610 0.72 MAPK1 (0.59) SMN1; SMN2RAB9ANPC1MAPK1POLB
SCHEMBL10270980 0.72 MAPK1 (0.59) SMN1; SMN2RAB9ANPC1MAPK1POLB
SCHEMBL22134881 0.68 FFAR1 (0.51) MAPK1
SCHEMBL16011728 0.68 MAPK1 (0.57) MAPTMAPK1CYP2C19CYP3A4PKM
SCHEMBL31044611 0.68 MAPK1 (0.57) MAPTMAPK1CYP2C19CYP3A4PKM
SCHEMBL16011559 0.68 MAPK1 (0.50) MAPK1L3MBTL1ACACB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12351570-B2 Disubstituted alkyne derivatives MERCK PATENT GMBH (DE) 2025-07-08 — — US disclosed
US-20230052586-A1 DISUBSTITUTED ALKYNE DERIVATIVES MERCK PATENT GMBH (DE) 2023-02-16 — — US disclosed
EP-3898588-B1 DISUBSTITUTED ALKYNE DERIVATIVES MERCK PATENT GMBH (DE) 2023-01-11 — — EP disclosed
EP-3898588-B1 DISUBSTITUTED ALKYNE DERIVATIVES MERCK PATENT GMBH (DE) 2023-01-11 — — EP disclosed
WO-2021249969-A1 COMBINATION PRODUCT FOR THE TREATMENT OF CANCER DISEASES MERCK PATENT GMBH (DE) 2021-12-16 — — WO disclosed
EP-3898588-A1 DISUBSTITUTED ALKYNE DERIVATIVES Merck Patent GmbH (DE) 2021-10-27 — — EP disclosed
WO-2020127960-A1 DISUBSTITUTED ALKYNE DERIVATIVES MERCK PATENT GMBH (DE) 2020-06-25 — — WO disclosed
WO-2020127960-A1 DISUBSTITUTED ALKYNE DERIVATIVES MERCK PATENT GMBH (DE) 2020-06-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12351570-B2 Disubstituted alkyne derivatives BRCA1, MYC, PCNA MAPT 3982/4885SMN1; SMN2 3127/4885RAB9A 3021/4885
US-20230052586-A1 DISUBSTITUTED ALKYNE DERIVATIVES BRCA1, MYC, PCNA MAPT 3982/4885SMN1; SMN2 3127/4885RAB9A 3021/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback